Researchers at the Biodesign Institute at Arizona State University have developed a new strategy to produce vaccines against viruses by targeting glycoproteins present on the virus surface. By combining HCV glycoproteins, E1 and E2, with portions of human antibodies (IgG), they produced a novel fusion protein with heterodimeric structure. In addition, they have successfully expressed protein components in plants—a promising medium for high production yields.
The fusion protein system ensures correct presentation of the HCV glycoproteins in their folded states, which guarantees generation of a robust immune response.
- Strategy to create vaccines against many viruses
- Synthetic vaccine for treatment against Hepatitis C Virus
Benefits and Advantages
- Targets specific functional proteins on viruses
- High yields of protein components with plant based expression
- Specific immunogenicity